Novartis Scores Back-To-Back Jury Wins in Bone Cancer Drug Labeling Suits


Novartis and Hollingsworth, its national counsel in litigation over the cancer drug Zometa, got a double dose of good news in the past week with federal juries in Kentucky and St. Louis throwing out failure-to-warn claims by plaintiffs who blamed the company for their jaw disease.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202541365010

Thank you!

This article's comments will be reviewed.